Adtran expands ALM with deep PON assurance for FTTX network monitoring
12.7.2023 15:00:00 EEST | Business Wire | Press release
Adtran today announced the extension of its ALM infrastructure assurance solution, enabling simple and cost-efficient fiber monitoring of passive optical networks (PON). Already widely deployed in other types of network architecture, the technology now provides deep PON assurance, enabling communication service providers (CSPs) to monitor their entire PON infrastructure for any faults or degradation. Until today, assuring PON networks was challenging and expensive. Now there’s a simple and cost-efficient way to leverage real-time insight so that maintenance teams can quickly locate and resolve issues before they affect customers. PON networks are critical for the delivery of high-speed connectivity to millions of homes and businesses. The ability to comprehensively monitor this essential part of the network will deliver major benefits in terms of performance, reliability and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230712070000/en/
Adtran’s ALM deep PON assurance technology is a unique solution that will provide CSPs with granular insight into their PON networks. (Photo: Business Wire)
“The evolution of our ALM device to include deep PON assurance marks a major milestone for the industry and for our company. It’s the first time since the merger of Adtran and ADVA that our combined technology teams have released a solution that shows the close synergies between the organizations,” said Christoph Glingener, CTO of Adtran. “We are major players in both the PON and fiber assurance spaces with rapidly growing market shares. By utilizing our expertise in these areas, we’ve developed a unique solution that could have an enormous impact on CSPs’ opex costs. For the first time, they will be able to both monitor and manage their PON networks in one pane of glass. This will provide CSPs with more insight and granular control than ever before. And because our deep PON assurance technology works through splitters, we’re able to keep capex costs low.”
Adtran’s ALM technology for in-service fiber monitoring is available immediately and can be easily integrated into existing fiber-to-the-home, fiber-to-the-business or any other FTTX network. The non-intrusive, service-agnostic deep PON assurance solution eliminates the need for demarcation reflectors in the field, ensuring compatibility with any existing PON network while reducing operational complexity. Offering valuable insights into passive network quality, it acts like a radar to pinpoint the location of issues. Featuring fanless operation and low-power consumption, the ultra-compact ALM enhances operational efficiency and sustainability. CSPs can quickly check the status of their PON network through Adtran’s web-based GUI, Ensemble Controller network management platform or a dedicated mobile application for on-the-go access.
“Our ALM assurance platform is already recognized as the gold standard for fiber monitoring in optical networks. With our deep PON assurance innovation, we’re extending its benefits to many more customers, enabling FTTX network operators to dramatically shorten repair cycles and avoid unnecessary truck rolls. This breakthrough technology will transform how CSPs manage their PON infrastructure, enabling them to provide a better customer experience while reducing costs and improving sustainability,” commented Sander Jansen, GM of Infrastructure Monitoring at Adtran. “We’re excited to help our customers unlock the full potential of their PON networks and provide them with the real-time insights they need to optimize performance and reduce their carbon footprint.”
Further information on Adtran’s ALM deep PON assurance technology is available in these slides.
A supporting product video is also available to watch.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and Twitter.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230712070000/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public-relations@adva.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
